The biology of reactive intermediates in systemic lupus erythematosus

References

• Jezek P, Zackova M, Ruzicka M, Skobisova E, Jaburek M. Mitochondrial uncoupling proteins—Facts and fantasies. Physiol Res. 2004; 53 Suppl 1: S199–S211.
   PubMedGoogle Scholar
• Bendall JK, Alp NJ, Warrick N, Cai S, Adlam D, Rockett K, Yokoyama M, Kawashima S, Channon KM. Stoichiometric relationships between endothelial tetrahydrobiopterin, endothelial NO synthase (eNOS) activity, and eNOS coupling in vivo: Insights from transgenic mice with endothelial-targeted GTP cyclohydrolase 1 and eNOS overexpression. Circ Res. 2005; 97 9: 864–871.
   PubMedGoogle Scholar
• Oates JC, Gilkeson GS. The biology of nitric oxide and other reactive intermediates in systemic lupus erythematosus. Clin Immunol. 2006; 121 3: 243–250.
   PubMed Web of Science ®Google Scholar
• Espey MG, Thomas DD, Miranda KM, Wink DA. Focusing of nitric oxide mediated nitrosation and oxidative nitrosylation as a consequence of reaction with superoxide. Proc Natl Acad Sci USA. 2002; 99 17: 11127–11132.
   PubMedGoogle Scholar
• Tannenbaum SR, White FM. Regulation and specificity of S-nitrosylation and denitrosylation. ACS Chem Biol. 2006; 1 10: 615–618.
   PubMedGoogle Scholar
• Moore KP, Darley-Usmar V, Morrow J, Roberts LJII. Formation of F2-isoprostanes during oxidation of human low-density lipoprotein and plasma by peroxynitrite. Circ Res. 1995; 77 2: 335–341.
   PubMedGoogle Scholar
• Goodwin DC, Landino LM, Marnett LJ. Reactions of prostaglandin endoperoxide synthase with nitric oxide and peroxynitrite. Drug Metab Rev. 1999; 31 1: 273–294.
   PubMed Web of Science ®Google Scholar
• Ridnour LA, Thomas DD, Mancardi D, Espey MG, Miranda KM, Paolocci N, Feelisch M, Fukuto J, Wink DA. The chemistry of nitrosative stress induced by nitric oxide and reactive nitrogen oxide species. Putting perspective on stressful biological situations. Biol Chem. 2004; 385 1: 1–10.
   PubMed Web of Science ®Google Scholar
• Thomas DD, Ridnour LA, Isenberg JS, Flores-Santana W, Switzer CH, Donzelli S, Hussain P, Vecoli C, Paolocci N, Ambs S, . The chemical biology of nitric oxide: Implications in cellular signaling. Free Radic Biol Med. 2008; 45 1: 18–31.
   PubMed Web of Science ®Google Scholar
• Leon L, Jeannin JF, Bettaieb A. Post-translational modifications induced by nitric oxide (NO): Implication in cancer cells apoptosis. Nitric Oxide. 2008; 19 2: 77–83.
   PubMedGoogle Scholar
• Delgado Alves J, Mason LJ, Ames PR, Chen PP, Rauch J, Levine JS, Subang R, Isenberg DA. Antiphospholipid antibodies are associated with enhanced oxidative stress, decreased plasma nitric oxide and paraoxonase activity in an experimental mouse model. Rheumatology (Oxford). 2005; 44 10: 1238–1244.
   PubMedGoogle Scholar
• Zou MH, Yesilkaya A, Ullrich V. Peroxynitrite inactivates prostacyclin synthase by heme-thiolate-catalyzed tyrosine nitration. Drug Metab Rev. 1999; 31 2: 343–349.
   PubMed Web of Science ®Google Scholar
• Oates JC, Christensen EF, Reilly CM, Self SE, Gilkeson GS. Prospective measure of serum 3-nitrotyrosine levels in systemic lupus erythematosus: Correlation with disease activity. Proc Assoc Am Physicians. 1999; 111 6: 611–621.
   PubMedGoogle Scholar
• Oates JC, Levesque MC, Hobbs MR, Smith EG, Molano ID, Page GP, Hill BS, Weinberg JB, Cooper GS, Gilkeson GS. Nitric oxide synthase 2 promoter polymorphisms and systemic lupus erythematosus in African-Americans. J Rheumatol. 2003; 30 1: 60–67.
   PubMedGoogle Scholar
• Kuhn A, Fehsel K, Lehmann P, Krutmann J, Ruzicka T, Kolbbachofen V. Aberrant timing in epidermal expression of inducible nitric oxide synthase after UV irradiation in cutaneous lupus erythematosus. J Invest Dermatol. 1998; 111 1: 149–153.
   PubMed Web of Science ®Google Scholar
• Belmont HM, Levartovsky D, Goel A, Amin A, Giorno R, Rediske J, Skovron ML, Abramson SB. Increased nitric oxide production accompanied by the up-regulation of inducible nitric oxide synthase in vascular endothelium from patients with systemic lupus erythematosus. Arthritis Rheum. 1997; 40 10: 1810–1816.
   PubMedGoogle Scholar
• El-Magadmi M, Bodill H, Ahmad Y, Durrington PN, Mackness M, Walker M, Bernstein RM, Bruce IN. Systemic lupus erythematosus: An independent risk factor for endothelial dysfunction in women. Circulation. 2004; 110 4: 399–404.
   PubMedGoogle Scholar
• Clancy R, Marder G, Martin V, Belmont HM, Abramson SB, Buyon J. Circulating activated endothelial cells in systemic lupus erythematosus: Further evidence for diffuse vasculopathy. Arthritis Rheum. 2001; 44 5: 1203–1208.
   PubMedGoogle Scholar
• Oates JC, Shaftman SR, Self SE, Gilkeson GS. Association of serum nitrate and nitrite levels with longitudinal assessments of disease activity and damage in systemic lupus erythematosus and lupus nephritis. Arthritis Rheum. 2008; 58 1: 263–272.
   PubMedGoogle Scholar
• Furusu A, Miyazaki M, Abe K, Tsukasaki S, Shioshita K, Sasaki O, Miyazaki K, Ozono Y, Koji T, Harada T, . Expression of endothelial and inducible nitric oxide synthase in human glomerulonephritis. Kidney Int. 1998; 53 6: 1760–1768.
   PubMedGoogle Scholar
• Wang JS, Tseng HH, Shih DF, Jou HS, Ger LP. Expression of inducible nitric oxide synthase and apoptosis in human lupus nephritis. Nephron. 1997; 77 4: 404–411.
   PubMedGoogle Scholar
• Bollain YGJJ, Ramirez-Sandoval R, Daza L, Esparza E, Barbosa O, Ramirez D, Pacheco-Tovar G, Avalos-Diaz E, Rodriguez-Padilla C, Herrera-Esparza R. Widespread expression of inducible NOS and citrulline in lupus nephritis tissues. Inflamm Res. 2009; 58 2: 61–66.
   Google Scholar
• Zheng L, Sinniah R, Hong Hsu SI. Renal cell apoptosis and proliferation may be linked to nuclear factor-kappaB activation and expression of inducible nitric oxide synthase in patients with lupus nephritis. Hum Pathol. 2006; 37 6: 637–647.
   PubMedGoogle Scholar
• Khan F, Ali R. Antibodies against nitric oxide damaged poly L-tyrosine and 3-nitrotyrosine levels in systemic lupus erythematosus. J Biochem Mol Biol. 2006; 39 2: 189–196.
   PubMedGoogle Scholar
• Dixit K, Ali R. Role of nitric oxide modified DNA in the etiopathogenesis of systemic lupus erythematosus. Lupus. 2004; 13 2: 95–100.
   PubMedGoogle Scholar
• Habib S, Moinuddin Ali R. Peroxynitrite-modified DNA: A better antigen for systemic lupus erythematosus anti-DNA autoantibodies. Biotechnol Appl Biochem. 2006; 43 Pt 2: 65–70.
   PubMedGoogle Scholar
• Huber J, Bochkov VN, Binder BR, Leitinger N. The isoprostane 8-iso-PGE2 stimulates endothelial cells to bind monocytes via cyclic AMP- and p38 MAP kinase-dependent signaling pathways. Antioxid Redox Signal. 2003; 5 2: 163–169.
   PubMedGoogle Scholar
• Fukunaga M, Makita N, Roberts LJII, Morrow JD, Takahashi K, Badr KF. Evidence for the existence of F2-isoprostane receptors on rat vascular smooth muscle cells. Am J Physiol. 1993; 246 6: C1619–C1624.
   Google Scholar
• Lopez LR, Kobayashi K, Matsunami Y, Matsuura E. Immunogenic oxidized low-density lipoprotein/beta2-glycoprotein I complexes in the diagnostic management of atherosclerosis. Clin Rev Allergy Immunol. 2009; 37 1: 12–19.
   PubMedGoogle Scholar
• Heery JM, Kozak M, Stafforini DM, Jones DA, Zimmerman GA, McIntyre TM, Prescott SM. Oxidatively modified LDL contains phospholipids with platelet-activating factor-like activity and stimulates the growth of smooth muscle cells. J Clin Invest. 1995; 96 5: 2322–2330.
   PubMed Web of Science ®Google Scholar
• Peng DQ, Brubaker G, Wu Z, Zheng L, Willard B, Kinter M, Hazen SL, Smith JD. Apolipoprotein A-I tryptophan substitution leads to resistance to myeloperoxidase-mediated loss of function. Arterioscler Thromb Vasc Biol. 2008; 28 11: 2063–2070.
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Hazen SL. Myeloperoxidase, modified lipoproteins, and atherogenesis. J Lipid Res. 2009; 50 Suppl:S346–S351.
   Google Scholar
• Nagy G, Koncz A, Perl A. T cell activation-induced mitochondrial hyperpolarization is mediated by Ca2+- and redox-dependent production of nitric oxide. J Immunol. 2003; 171 10: 5188–5197.
   PubMedGoogle Scholar
• Gergely PJr, Niland B, Gonchoroff N, Pullmann RJr, Phillips PE, Perl A. Persistent mitochondrial hyperpolarization, increased reactive oxygen intermediate production, and cytoplasmic alkalinization characterize altered IL-10 signaling in patients with systemic lupus erythematosus. J Immunol. 2002; 169 2: 1092–1101.
   PubMed Web of Science ®Google Scholar
• Nagy G, Barcza M, Gonchoroff N, Phillips PE, Perl A. Nitric oxide-dependent mitochondrial biogenesis generates Ca2+ signaling profile of lupus T cells. J Immunol. 2004; 173 6: 3676–3683.
   PubMed Web of Science ®Google Scholar
• Gergely PJr, Grossman C, Niland B, Puskas F, Neupane H, Allam F, Banki K, Phillips PE, Perl A. Mitochondrial hyperpolarization and ATP depletion in patients with systemic lupus erythematosus. Arthritis Rheum. 2002; 46 1: 175–190.
   PubMed Web of Science ®Google Scholar
• Fernandez DR, Telarico T, Bonilla E, Li Q, Banerjee S, Middleton FA, Phillips PE, Crow MK, Oess S, Muller-Esterl W, . Activation of mammalian target of rapamycin controls the loss of TCRzeta in lupus T cells through HRES-1/Rab4-regulated lysosomal degradation. J Immunol. 2009; 182 4: 2063–2073.
   PubMed Web of Science ®Google Scholar
• Weinberg JB, Granger DL, Pisetsky DS, Seldin MF, Misukonis MA, Mason SN, Pippen AM, Ruiz P, Wood ER, Gilkeson GS. The role of nitric oxide in the pathogenesis of spontaneous murine autoimmune disease: Increased nitric oxide production and nitric oxide synthase expression in MRL-lpr/lpr mice, and reduction of spontaneous glomerulonephritis and arthritis by orally administered NG-monomethyl-L-arginine. J Exp Med. 1994; 179 2: 651–660.
   PubMed Web of Science ®Google Scholar
• Keng T, Privalle CT, Gilkeson GS, Weinberg JB. Peroxynitrite formation and decreased catalase activity in autoimmune MRL-lpr/lpr mice. Mol Med. 2000; 6 9: 779–792.
   PubMedGoogle Scholar
• Wang HP, Hsu TC, Hsu GJ, Li SL, Tzang BS. Cystamine attenuates the expressions of NOS- and TLR-associated molecules in the brain of NZB/W F1 mice. Eur J Pharmacol. 2009; 607 1–3: 102–106.
   PubMedGoogle Scholar
• Qing X, Zavadil J, Crosby MB, Hogarth MP, Hahn BH, Mohan C, Gilkeson GS, Bottinger EP, Putterman C. Nephritogenic anti-DNA antibodies regulate gene expression in MRL/lpr mouse glomerular mesangial cells. Arthritis Rheum. 2006; 54 7: 2198–2210.
   PubMedGoogle Scholar
• Mishra N, Reilly CM, Brown DR, Ruiz P, Gilkeson GS. Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse. J Clin Invest. 2003; 111 4: 539–552.
   PubMed Web of Science ®Google Scholar
• Reilly CM, Olgun S, Goodwin D, Gogal RMJr, Santo A, Romesburg JW, Ahmed SA, Gilkeson GS. Interferon regulatory factor-1 gene deletion decreases glomerulonephritis in MRL/lpr mice. Eur J Immunol. 2006; 36 5: 1296–1308.
   PubMedGoogle Scholar
• Li HH, Cheng HH, Sun KH, Wei CC, Li CF, Chen WC, Wu WM, Chang MS. Interleukin-20 targets renal mesangial cells and is associated with lupus nephritis. Clin Immunol. 2008; 129 2: 277–285.
   PubMedGoogle Scholar
• Takeda Y, Takeno M, Iwasaki M, Kobayashi H, Kirino Y, Ueda A, Nagahama K, Aoki I, Ishigatsubo Y. Chemical induction of HO-1 suppresses lupus nephritis by reducing local iNOS expression and synthesis of anti-dsDNA antibody. Clin Exp Immunol. 2004; 138 2: 237–244.
   PubMedGoogle Scholar
• Lui SL, Tsang R, Wong D, Chan KW, Chan TM, Fung PC, Lai KN. Effect of mycophenolate mofetil on severity of nephritis and nitric oxide production in lupus-prone MRL/lpr mice. Lupus. 2002; 11 7: 411–418.
   PubMed Web of Science ®Google Scholar
• Yu CC, Yang CW, Wu MS, Ko YC, Huang CT, Hong JJ, Huang CC. Mycophenolate mofetil reduces renal cortical inducible nitric oxide synthase mRNA expression and diminishes glomerulosclerosis in MRL/lpr mice. J Lab Clin Med. 2001; 138 1: 69–77.
   PubMedGoogle Scholar
• Reilly CM, Farrelly LW, Viti D, Redmond ST, Hutchison F, Ruiz P, Manning P, Connor J, Gilkeson GS. Modulation of renal disease in MRL/lpr mice by pharmacologic inhibition of inducible nitric oxide synthase. Kidney Int. 2002; 61 3: 839–846.
   PubMedGoogle Scholar
• Oates JC, Ruiz P, Alexander A, Pippen AM, Gilkeson GS. Effect of late modulation of nitric oxide production on murine lupus. Clin Immunol Immunopathol. 1997; 83 1: 86–92.
   PubMedGoogle Scholar
• Gilkeson GS, Mudgett JS, Seldin MF, Ruiz P, Alexander AA, Misukonis MA, Pisetsky DS, Weinberg JB. Clinical and serologic manifestations of autoimmune disease in MRL-lpr/lpr mice lacking nitric oxide synthase type 2. J Exp Med. 1997; 186 3: 365–373.
   PubMedGoogle Scholar
• Njoku C, Self SE, Ruiz P, Hofbauer AF, Gilkeson GS, Oates JC. Inducible nitric oxide synthase inhibitor SD-3651 reduces proteinuria in MRL/lpr mice deficient in the NOS2 gene. J Investig Med. 2008; 56 7: 911–919.
   PubMedGoogle Scholar
• Zou MH, Cohen R, Ullrich V. Peroxynitrite and vascular endothelial dysfunction in diabetes mellitus. Endothelium. 2004; 11 2: 89–97.
   PubMed Web of Science ®Google Scholar
• Zou MH, Shi C, Cohen RA. Oxidation of the zinc-thiolate complex and uncoupling of endothelial nitric oxide synthase by peroxynitrite. J Clin Invest. 2002; 109 6: 817–826.
   PubMed Web of Science ®Google Scholar
• Casciola-Rosen LA, Anhalt G, Rosen A. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med. 1994; 179 4: 1317–1330.
   PubMed Web of Science ®Google Scholar
• Boyd CS, Cadenas E. Nitric oxide and cell signaling pathways in mitochondrial-dependent apoptosis. Biol Chem. 2002; 383 3–4: 411–423.
   PubMed Web of Science ®Google Scholar
• Oates JC, Gilkeson GS. Nitric oxide induces apoptosis in spleen lymphocytes from MRL/lpr mice. J Investig Med. 2004; 52 1: 62–71.
   PubMedGoogle Scholar
• Singh AK. Lupus in the Fas lane?. J Royal Coll Phys Lond. 1995; 29 6: 475–478.
   PubMedGoogle Scholar
• Njoku CJ, Patrick KS, Ruiz PJr., Oates JC. Inducible nitric oxide synthase inhibitors reduce urinary markers of systemic oxidant stress in murine proliferative lupus nephritis. J Investig Med. 2005; 53 7: 347–352.
   PubMed Web of Science ®Google Scholar
• Thomas DD, Espey MG, Ridnour LA, Hofseth LJ, Mancardi D, Harris CC, Wink DA. Hypoxic inducible factor 1alpha, extracellular signal-regulated kinase, and p53 are regulated by distinct threshold concentrations of nitric oxide. Proc Natl Acad Sci USA. 2004; 101 24: 8894–8899.
   PubMedGoogle Scholar
• Zhang J, Jin B, Li L, Block ER, Patel JM. Nitric oxide-induced persistent inhibition and nitrosylation of active site cysteine residues of mitochondrial cytochrome-c oxidase in lung endothelial cells. Am J Physiol Cell Physiol. 2005; 288 4: C840–C849.
   Google Scholar